

Press Release

Farmako appoints Katrin Eckmans as CEO

Frankfurt am Main, 19 July 2019. The Frankfurt-based pharmaceutical wholesale company, Farmako, announces today the new appointment of the CEO position. Katrin Eckmans, a business graduate with many years of management experience, has taken over the management of the company as of 18 July. She joined Farmako as Head of Business Development already in March 2019. Founder and majority shareholder Sebastian Diemer will continue to be strongly involved in the company. The co-shareholders Heartbeat Labs and Nikita Fahrenholz will remain on board with a minority stake.

"We are convinced that Katrin's experience and leadership skills will lead our company towards a new path of success," says Sebastian Diemer, founder of Farmako. Germany is the most important market for medical cannabis in Europe and will continue to grow at high rates. Also on a European and international basis the market is still at the very beginning of its development. With our team of around 10 people we are very well positioned to further expand our distribution business with strong suppliers and new products".

Farmako was established at the end of 2018 as a pharmaceutical wholesaler and is specialized in the distribution of pharmaceutical cannabis. It has been holding the necessary distribution licenses since February 2019. The company has achieved revenues of over 1.3 million euros since March 2019. In July 2019 the shareholders have announced to separate Farmako's business areas and spin-off the biosynthesis arm into a separate company with Heartbeat Labs as majority shareholder.

"The spin-off of the biosynthesis arm allows Farmako to fully re-focus on its core business, the wholesale of medical cannabis and the distribution to pharmacies", says Katrin Eckmans, CEO of Farmako GmbH. "Farmako is an exciting company with large potential, and I am very pleased to take over my new task. Together with strong investors and our well-established team we will continue to counteract the existing supply shortage and provide an increasing number of patients with access to the necessary cannabis medicines".

Katrin Eckmans studied business administration and worked as an M&A analyst at BNP Paribas before becoming a project director in the infrastructure sector. Prior to joining Farmako, she worked for around 10 years on various international projects at Fraport AG, including the management of airport acquisitions and investments in Brazil, Greece, Russia and Turkey. She has been Head of Business Development at Farmako since March 2019.

About Farmako

Farmako GmbH is a pharmaceutical wholesale company based in Frankfurt, Germany. The company focuses on the distribution of medical cannabis to pharmacies with the aim of closing the shortage in the supply of cannabis medicines to patients. Farmako is planning to expand its business into further European countries with a corresponding legal framework. Farmako already has branches in Germany, Denmark and the United Kingdom.

Press Contact

presse@farmako.de